(Q53098848)

English

Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

author name string

Rianne J M Lammers

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

Joan Palou

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

Wim P J Witjes

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

Maria H D Janzing-Pastors

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

Christien T M Caris

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

J Alfred Witjes

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

publication date

1 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

114

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

193-201

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Adherence to Surveillance Among Patients With Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12495

21 January 2018

Identifiers

10.1111/BJU.12495

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24304638

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53098848&oldid=903173036"